Sonnet BioTherapeutics

Sonnet BioTherapeutics is a biotechnology company focused on oncology, with a proprietary platform for innovative mono- or bispecific, bifunctional biologics. The technology, known as FHAB (Fully Human Albumin Binding), utilizes fully human single-chain antibody fragments (scFv) to bind with human serum albumin (HSA) and "hitchhike" to the target tissue. Sonnet's FHAB targets tumors and lymphoid tissues, providing an improved therapeutic window for optimizing the safety and efficacy of immune-modulatory biologics. FHAB serves as the foundation for a modular, plug-and-play architecture designed to enhance a range of large molecule therapeutic categories, including cytokines, peptides, antibodies, and vaccines.